PK/PD Modeling of the PDE7 Inhibitor—GRMS-55 in a Mouse Model of Autoimmune Hepatitis

This study aimed to assess the efficacy and explore the mechanisms of action of a potent phosphodiesterase (PDE)7A and a moderate PDE4B inhibitor GRMS-55 in a mouse model of autoimmune hepatitis (AIH). The concentrations of GRMS-55 and relevant biomarkers were measured in the serum of BALB/c mice with concanavalin A (ConA)-induced hepatitis administered with GRMS-55 at two dose levels. A semi-mechanistic PK/PD/disease progression model describing the time courses of measured biomarkers was developed. The emetogenicity as a potential side effect of the studied compound was evaluated in the α2-adrenoceptor agonist-induced anesthesia model. The results indicate that liver damage observed in mice challenged with ConA was mainly mediated by TNF-α and IFN-γ. GRMS-55 decreased the levels of pro-inflammatory mediators and the transaminase activities in the serum of mice with AIH. The anti-inflammatory properties of GRMS-55, resulting mainly from PDE7A inhibition, led to a high hepatoprotective activity in mice with AIH, which was mediated by an inhibition of pro-inflammatory signaling. GRMS-55 did not induce the emetic-like behavior. The developed PK/PD/disease progression model may be used in future studies to assess the potency and explore the mechanisms of action of new investigational compounds for the treatment of AIH.

[1]  E. Wyska,et al.  Comparative Assessment of the New PDE7 Inhibitor – GRMS-55 and Lisofylline in Animal Models of Immune-Related Disorders: A PK/PD Modeling Approach , 2020, Pharmaceutical Research.

[2]  U. Christen.  Animal models of autoimmune hepatitis. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[3]  D. Lewin,et al.  Differential Diagnosis of Hepatic Necrosis Encountered at Autopsy , 2018, Academic forensic pathology.

[4]  Yixian Liao,et al.  Structure-based design and structure-activity relationships of 1,2,3,4-tetrahydroisoquinoline derivatives as potential PDE4 inhibitors. , 2018, Bioorganic & medicinal chemistry letters.

[5]  Tinghong Ye,et al.  Comparison of Concanavalin a-Induced Murine Autoimmune Hepatitis Models , 2018, Cellular Physiology and Biochemistry.

[6]  M. Kołaczkowski,et al.  Novel butanehydrazide derivatives of purine-2,6-dione as dual PDE4/7 inhibitors with potential anti-inflammatory activity: Design, synthesis and biological evaluation. , 2018, European journal of medicinal chemistry.

[7]  D. Vergani,et al.  Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments , 2017, World journal of gastroenterology.

[8]  E. Wyska,et al.  PK/PD studies on non-selective PDE inhibitors in rats using cAMP as a marker of pharmacological response , 2017, Naunyn-Schmiedeberg's Archives of Pharmacology.

[9]  D. DuBois,et al.  Modeling Combined Immunosuppressive and Anti-inflammatory Effects of Dexamethasone and Naproxen in Rats Predicts the Steroid-Sparing Potential of Naproxen , 2017, Drug Metabolism and Disposition.

[10]  Ming Niu,et al.  Sophocarpine Protects Mice from ConA-Induced Hepatitis via Inhibition of the IFN-Gamma/STAT1 Pathway , 2017, Front. Pharmacol..

[11]  M. Weltman,et al.  The use of immunosuppression in autoimmune hepatitis: A current literature review , 2017, Clinical and molecular hepatology.

[12]  M. Pawłowski,et al.  PDE7-Selective and Dual Inhibitors: Advances in Chemical and Biological Research. , 2017, Current medicinal chemistry.

[13]  K. Taskén,et al.  Molecular Mechanisms for cAMP-Mediated Immunoregulation in T cells – Role of Anchored Protein Kinase A Signaling Units , 2016, Front. Immunol..

[14]  Y. Oo,et al.  Autoimmune Hepatitis: Progress from Global Immunosuppression to Personalised Regulatory T Cell Therapy , 2016, Canadian journal of gastroenterology & hepatology.

[15]  A. Czaja.  Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future Directions , 2016, Gut and liver.

[16]  Shaojun Zhao,et al.  A novel recombinant slow-release TNF α-derived peptide effectively inhibits tumor growth and angiogensis , 2015, Scientific Reports.

[17]  Justin C. Earp,et al.  Modeling effects of dexamethasone on disease progression of bone mineral density in collagen-induced arthritic rats , 2015, Pharmacology research & perspectives.

[18]  F. Tacke,et al.  The concanavalin A model of acute hepatitis in mice , 2015, Laboratory animals.

[19]  G. Dalekos,et al.  Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics. , 2015, World journal of gastroenterology.

[20]  Y. Wan,et al.  Inhibitory effect of liposomal quercetin on acute hepatitis and hepatic fibrosis induced by concanavalin A , 2014, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.

[21]  Kewei Wang,et al.  Molecular mechanisms of hepatic apoptosis , 2014, Cell Death and Disease.

[22]  Man Liu,et al.  Immune mechanisms of Concanavalin A model of autoimmune hepatitis. , 2012, World journal of gastroenterology.

[23]  M. Ota,et al.  Cytokine profiles affecting the pathogenesis of autoimmune hepatitis in Japanese patients , 2011, Hepatology research : the official journal of the Japan Society of Hepatology.

[24]  J. Palacios,et al.  The human area postrema and other nuclei related to the emetic reflex express cAMP phosphodiesterases 4B and 4D , 2010, Journal of Chemical Neuroanatomy.

[25]  Saleh M. Ibrahim,et al.  Cytokines and Cytokine Profiles in Human Autoimmune Diseases and Animal Models of Autoimmunity , 2009, Mediators of inflammation.

[26]  T. Nakatsuka,et al.  Inhibition of phosphodiesterase 7A ameliorates Concanavalin A-induced hepatitis in mice. , 2009, International immunopharmacology.

[27]  T. Nakatsuka,et al.  Effect of phosphodiesterase 7 inhibitor ASB16165 on development and function of cytotoxic T lymphocyte. , 2009, International immunopharmacology.

[28]  M. Pruniaux,et al.  Phosphodiesterase (PDE) 7 in inflammatory cells from patients with asthma and COPD. , 2007, Pulmonary pharmacology & therapeutics.

[29]  A. Ichikawa,et al.  The effects of a novel phosphodiesterase 7A and -4 dual inhibitor, YM-393059, on T-cell-related cytokine production in vitro and in vivo. , 2006, European journal of pharmacology.

[30]  Kam Y. J. Zhang,et al.  Keynote review: phosphodiesterase-4 as a therapeutic target. , 2005, Drug discovery today.

[31]  T. Fukuda,et al.  Therapeutic administration of Y-40138, a multiple cytokine modulator, inhibits concanavalin A-induced hepatitis in mice. , 2005, European journal of pharmacology.

[32]  S. Seki,et al.  Immunohistochemical detection of Fas and apoptosis in type-1 autoimmune hepatitis. , 2003, Hepato-gastroenterology.

[33]  S. Jin,et al.  Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. , 2002, The Journal of clinical investigation.

[34]  C. Chan,et al.  PDE4 inhibitors induce emesis in ferrets via a noradrenergic pathway , 2001, Neuropharmacology.

[35]  F. Nicoletti,et al.  ESSENTIAL PATHOGENETIC ROLE FOR INTERFERON (IFN-)γ IN CONCANAVALIN A-INDUCED T CELL-DEPENDENT HEPATITIS: EXACERBATION BY EXOGENOUS IFN-γ AND PREVENTION BY IFN-γ RECEPTOR-IMMUNOGLOBULIN FUSION PROTEIN , 2000 .

[36]  A. Billiau,et al.  Bimodal role of endogenous interleukin‐6 in concanavalin A‐induced hepatitis in mice , 2000, Journal of leukocyte biology.

[37]  R. Batey,et al.  IL‐6, IFN‐γ and TNF‐α production by liver‐associated T cells and acute liver injury in rats administered concanavalin A , 1998 .

[38]  I. van Ark,et al.  Differential Effects of Endogenous and Exogenous Interferon- γ on Immunoglobulin E, Cellular Infiltration, and Airway Responsiveness in a Murine Model of Allergic Asthma , 1998 .

[39]  Z. Halpern,et al.  Pentoxifylline prevents concanavalin A-induced hepatitis by reducing tumor necrosis factor alpha levels and inhibiting adhesion of T lymphocytes to extracellular matrix. , 1998, Journal of hepatology.

[40]  R. Batey,et al.  IL-6, IFN-gamma and TNF-alpha production by liver-associated T cells and acute liver injury in rats administered concanavalin A. , 1998, Immunology and cell biology.

[41]  A. Wendel,et al.  Protection from T cell-mediated murine liver failure by phosphodiesterase inhibitors. , 1997, The Journal of pharmacology and experimental therapeutics.

[42]  P. Barnes,et al.  Identification of cyclic AMP phosphodiesterases 3, 4 and 7 in human CD4+ and CD8+ T‐lymphocytes: role in regulating proliferation and the biosynthesis of interleukin‐2 , 1996, British journal of pharmacology.

[43]  M. Leist,et al.  Concanavalin A—induced T‐cell—mediated hepatic injury in mice: The role of tumor necrosis factor , 1995, Hepatology.

[44]  M. Manns,et al.  Experimental autoimmune hepatitis: Disease induction, time course and t‐cell reactivity , 1990, Hepatology.

[45]  P. Brandtzaeg,et al.  Brief Definitive Report the Complex Pattern of Cytokines in Serum from Patients with Meningococcal Septic Shock Association between Interleukin 6, Interleukin 1, and Fatal Outcome , 2022 .